Neurographic Evidence of Inflammatory Polyneuropathies in Peri-COVID-19 Circumstances and Their Relationship With Acute Disease Severity and Inflammatory Storm

Hasrat, Nareen H; Kadhum, Haithem J; Hashim, Ali Raheem; Yakob, Zaineb A; Kadhim, Lana A; Farid, Hassan A

doi:10.7759/cureus.23517

Cited by 2 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With the COVID-19 pandemic spread, most of the literature highlights the acute post-infectious polyneuropathy, formerly known as Guillain-Barré syndrome (GBS), as the literature reported a 5.41-fold increase in GBS cases in 2020 compared to 2017-2019 [7]. According to a recent cohort study from Basrah, the prevalence of GBS and chronic inflammatory demyelinating polyneuropathy (CIDP) is six times higher in the COVID-19 population compared to the non-COVID-19 sample [8]. However, mononeuritis multiplex was found in a large proportion of the patients (11 of 69, 16%) with severe COVID-19 admitted to the intensive care units [9].…”

Section: Discussionmentioning

confidence: 99%

Clinical and Neurophysiological Evidence of Mononeuritis Multiplex During the COVID-19 Era

Hasrat¹,

Kadhum²,

Hashim³

et al. 2023

Cureus

Self Cite

View full text Add to dashboard Cite

Infection with the novel coronavirus that causes coronavirus disease 2019 results in a variety of clinical symptoms, including various neurological abnormalities. Peripheral nervous system symptoms, such as peripheral neuropathies, were often recorded in the medical literature, primarily as Guillain-Barré syndrome. Mononeuropathy multiplex is a multifocal axonal neuropathy commonly associated with vasculitis or connective tissue disease. Recent evidence about its associations with severe COVID-19 infection and intensive care unit hospitalization is being considered. A 58-year-old man with clinical and electrophysiological confirmation of mononeuropathy multiplex was reported during the peri-COVID-19 illness. He was treated with steroids and achieved a satisfactory response. Therefore, clinical and neurophysiological evaluation is recommended for any patient presenting with neurological manifestations following COVID-19 infection.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical and Neurophysiological Evidence of Mononeuritis Multiplex During the COVID-19 Era

Hasrat¹,

Kadhum²,

Hashim³

et al. 2023

Cureus

Self Cite

View full text Add to dashboard Cite

show abstract

“…In 11 studies, a total of 61 GBS cases were reported over 132,132 SARS-CoV-2 hospitalized patients [27,[29][30][31][32][33][34][35][36][37][38]. The modelled proportion yielded 2.96 GBS cases per 1000 SARS-CoV-2 patients (95% CI 0.57; 6.75) (Figure 4a).…”

Section: Incidence Of Gbs In Sars-cov-2 Hospitalized Patientsmentioning

confidence: 99%

Guillain−Barré syndrome and SARS‐CoV‐2 infection: a systematic review and meta‐analysis on a debated issue and evidence for the ‘Italian factor’

Censi,

Bisaccia,

Gallina

et al. 2023

Euro J of Neurology

View full text Add to dashboard Cite

Background and purposeThe association between Guillain−Barré syndrome (GBS) and severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is debated. This study reappraises, after three pandemic years, the epidemiological data and the features of GBS in SARS‐CoV‐2 patients.MethodsA systematic review and meta‐analysis of case reports/series and cohort studies published between 1 January 2020 and 19 April 2023 was performed.ResultsIn all, 209 case reports/series (304 patients) and 26 cohort studies were included. The risk of GBS in northern Italy during the first pandemic wave was 2.85 times increased (95% confidence interval [CI] 1.54; 5.25) whereas in some countries the risk during the first pandemic year was 0.17 times reduced (risk ratio 0.83, 95% CI 0.75; 0.93). The incidence of GBS in SARS‐CoV‐2 Italian hospitalized cohorts was 8.55 per 1000 (95% CI 5.33; 12.49) with an estimated incidence of 0.13 GBS per 1000 in the SARS‐CoV‐2 infected population. In European cohorts the pooled rate of GBS with SARS‐CoV‐2 infection was 61.3% of the total. GBS patients with SARS‐CoV‐2 infection showed more frequently, but not differently from non‐infected patients, the classical clinical presentation and the demyelinating subtype. Cranial nerves were more frequently involved in SARS‐CoV‐2 infected patients.ConclusionsAn increased risk of GBS occurred in northern Italy during early COVID‐19 pandemic. The recognition of the ‘Italian factor’ reconciles contrasting results of the epidemiological studies. The slightly reduced GBS risk in other countries and the relatively high frequency of GBS associated with SARS‐CoV‐2 infection can be explained by the adopted health measures that decreased the circulation of other GBS infective antecedents.

show abstract

Neurographic Evidence of Inflammatory Polyneuropathies in Peri-COVID-19 Circumstances and Their Relationship With Acute Disease Severity and Inflammatory Storm

Cited by 2 publications

References 17 publications

Clinical and Neurophysiological Evidence of Mononeuritis Multiplex During the COVID-19 Era

Clinical and Neurophysiological Evidence of Mononeuritis Multiplex During the COVID-19 Era

Guillain−Barré syndrome and SARS‐CoV‐2 infection: a systematic review and meta‐analysis on a debated issue and evidence for the ‘Italian factor’

Contact Info

Product

Resources

About